BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
methotrexate Sensitive: C3 – Early Trials
|
methotrexate Sensitive: C3 – Early Trials
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
pixantrone Sensitive: C3 – Early Trials
|
pixantrone Sensitive: C3 – Early Trials
|
BCL2 positive
|
Estrogen Receptor Positive Breast Cancer
|
BCL2 positive
|
Estrogen Receptor Positive Breast Cancer
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
venetoclax + ibrutinib Sensitive: D – Preclinical
|
venetoclax + ibrutinib Sensitive: D – Preclinical
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive
|
Diffuse Large B Cell Lymphoma
|
venetoclax + fostamatinib Sensitive: D – Preclinical
|
venetoclax + fostamatinib Sensitive: D – Preclinical
|